One of the largest barriers to the effective treatment of HER2-positive breast cancers is the rapid acquisition of Herceptin-resistance [45, 46] often accompanied by significantly elevated levels of phosphorylated active AKT [47]. This evidence concerns the gene AKT1 and breast cancer.